Interleukin-23 Secreted by Activated Macrophages Drives γδT Cell Production of Interleukin-17 to Aggravate Secondary Injury After Intracerebral Hemorrhage

Qi Zhong, MS;* Kai Zhou, MD;* Qiao-Li Liang, MD, PhD;* Sen Lin, PhD; Yan-Chun Wang, MD; Xiao-Yi Xiong, MS; Zhao-You Meng, MS; Ting Zhao, MS; Wen-Yao Zhu, MS; Yuan-Rui Yang, MS; Mao-Fan Liao, BS; Qiu-Wen Gong, BS; Liang Liu, MS; Ao Xiong, BS; Junwei Hao, MD, PhD; Jian Wang, MD, PhD; Qing-Wu Yang, MS; Mao-Fan Liao, BS; Qiu-Wen Gong, BS; Liang Liu, MS; Ao Xiong, BS; Junwei Hao, MD, PhD; Jian Wang, MD, PhD; Qing-Wu Yang, MD, PhD

Background—Neuroinflammation plays a key role in intracerebral hemorrhage (ICH)–induced secondary brain injury, but the specific roles of peripheral inflammatory cells such as macrophages and lymphocytes remain unknown. The purpose of this study was to explore the roles of macrophages, T lymphocytes, and the cytokines they secrete as potential targets for treating secondary brain injury after ICH.

Methods and Results—Our results showed that peripheral macrophages and T lymphocytes successively infiltrated the brain, with macrophage counts peaking 1 day after ICH and T-lymphocyte counts peaking after 4 days. These peaks in cellular infiltration corresponded to increases in interleukin (IL)-23 and IL-17 expression, respectively. We found that hemoglobin from the hematoma activated IL-23 secretion by infiltrating macrophages by inducing the formation of toll-like receptor (TLR) 2/4 heterodimer. This increased IL-23 expression stimulated CD T-cell production of IL-17, which increased brain edema and neurologic deficits in the model mice as a proinflammatory factor. Finally, we found that sparstolonin B (SsnB) could ameliorate brain edema and neurologic deficits in ICH model mice via inhibition of TLR2/TLR4 heterodimer formation, and notably, SsnB interacted with myeloid differentiation factor 88 Arg196.

Conclusions—Together, our results reveal the importance of the IL-23/IL-17 inflammatory axis in secondary brain injury after ICH and thus provide a new therapeutic target for ICH treatment. (J Am Heart Assoc. 2016;5:e004340 doi: 10.1161/JAHA.116.004340)

Key Words: IL-17 • IL-23 • intracerebral hemorrhage • lymphocyte • macrophage • TLR2 • TLR4

Intracerebral hemorrhage (ICH) accounts for 20% to 30% of all cases of cerebrovascular disease in China and remains the leading cause of mortality, largely because there currently is no specific treatment.1–4 ICH is associated with both primary and secondary injury. The physical effects of the hematoma (mass effect) and disturbance of the adjacent tissue that occur within hours of the onset of bleeding represent the primary insult.4 The potential benefit of clot removal has been investigated in multiple clinical trials but not confirmed.4–6 Instead, most recent attempts to identify novel therapeutic targets have focused on the mechanisms responsible for ICH-induced secondary injury, which is caused by the development
of edema, free radicals, inflammation, and direct cellular toxicity of the degradation by products of the hematoma. Increasing evidence indicates that inflammation plays a critical role in ICH-induced secondary injury. Within minutes after ICH, microglia are activated and begin to release large amounts of cytokines and chemokines to destroy the blood-brain barrier (BBB). In the later phase, peripheral inflammatory cells such as macrophages and lymphocytes are mobilized to the perihematoma brain tissue through the damaged BBB. The infiltrating macrophages and T lymphocytes further produce proinflammatory factors to exacerbate brain edema and neurologic deficits after ICH. However, little is known about the mechanisms by which macrophages and lymphocytes are activated after ICH as well as the proinflammatory factors they release to induce the later brain injury.

Among the proinflammatory factors released within the injured brain, interleukin (IL)-17 generated by IL-17–expressing helper T (Th17) cells has been shown to induce inflammation in experimental autoimmune encephalomyelitis (EAE), which is a mouse model of multiple sclerosis. Research has also shown that IL-23, a heterodimer of the IL-23p19 and IL-12p40 subunits, released by activated macrophages and dendritic cells (DCs) can induce differentiation of CD4+ T cells into Th17 cells to generate a major inflammatory reaction. This IL-23/IL-17 inflammatory axis has been shown to be essential for the onset and progression of autoimmune inflammatory diseases in multiple mouse models, including EAE and collagen-induced arthritis. Moreover, the T-lymphocyte production of IL-17 in response to macrophage-derived IL-23 was found to play a critical role in the later stage of brain infarction. These data highlight an important role of the IL-23/IL-17 inflammatory axis in the acute neuroinflammatory response. However, the roles of macrophages and T lymphocytes as well as the IL-23/IL-17 inflammatory axis within the neuroinflammation that occurs after ICH remain to be determined.

The purpose of this study was to explore the roles of macrophages, T lymphocytes, and the cytokines they secrete in the secondary brain injury caused by ICH. ICH was induced using an established model in various lines of knockout mice, and the molecular events underlying the resulting neuroinflammatory responses were studied. The results of these experiments provide insight into the mechanisms of the neuroinflammation responsible for secondary brain injury after ICH and provide new targets for the development of therapies for ICH patients.

Materials and Methods

Animals
Male C57BL/6 mice, weighing 20 to 24 g, were obtained from the Animal Center of the Third Military Medical University (Chongqing, China). IL-17−/−, IL-23p19−/−, T-cell receptor (TCR) γδ−/− (γδT−/−), and TIR domain-containing adapter-inducing interferon-β (TRIF)−/− mice (male, 20–24 g) were purchased from the Jackson Laboratory (Bar Harbor, ME). TLR2−/−, TLR4−/−, myeloid differentiation factor 88 (MyD88)−/−, and Rag1−/− mice (20–24 g) were obtained from the Model Animal Research Institute of Nanjing University (Nanjing Biomedical Research Institute, Nanjing, China). Each knockout mouse model was backcrossed onto the C57BL/6 background. TLR2−/− and TLR4−/− mice were bred to obtain TLR2/TLR4 double-knockout mice (TLR2−/−/TLR4−/−), and TLR2 and TLR4 expression in mouse brain was assessed by Western blotting to identify the genotype of TLR2−/−/TLR4−/− mice, as previously reported. All animal experiments were performed in compliance with the Guide for the Care and Use of Laboratory Animals, 8th edition (2011) and ARRIVE (Animal Research: Reporting In Vivo Experiments) guidelines.

ICH Model
A previously reported model of ICH employing autologous blood was used in this study. After mice were anesthetized by intraperitoneal (i.p.) injection of 80 mg/kg phenobarbital, they were fixed on a mouse stereotaxic frame (Stoelting, Wood Dale, IL). Then 20 μL of autologous blood collected from the tail vein and not treated with an anticoagulant was injected into the caudate nucleus using a syringe pump (KD Scientific, Holliston, MA) at 0.8 mm anterior, 2 mm right lateral, and 3.5 mm deep from the bregma. During the procedure, body temperature was kept at 37°C, and the mice had free access to food and water once awake. Mice that died were excluded from the study.

Cell Isolation and Adoptive Transfer in Mice
Based on previously reported methods, CD3+ T lymphocytes (with a purity >90%) were isolated from the spleen of wild-type (WT) mice by following the manufacturer’s instructions for the mouse CD3ε microbead kit (Miltenyi Biotec, Cologne, Germany). The isolated CD3+ T lymphocytes (1 × 107) were transfused back into the Rag1−/− mice intravenously 5 days before ICH.

BM-Chimeric Mice
According to previously reported methods, recipient mice were given two doses (5-Gy) of total body radiation 4 hours apart. After irradiation, recipients received an injection of 1 × 107 donor bone marrow (BM) cells in the tail vein. Ly5.1 and Ly5.2 mice were used to confirm the success rate of chimerism. At 6 weeks after irradiation and BM transplantation, >99% of CD11b+ cells in the blood of irradiated Ly5.2 mice were of the donor (Ly5.1+) origin. ICH was induced in the
BM-chimeric mice according to the model described above at 7 weeks after irradiation and transplantation.

**Macrophage Depletion and CLP Administration**

Clodronate liposomes (CLPs) and control liposomes were purchased from FormuMax Scientific, Inc. (Palo Alto, CA) and injected intraperitoneally 1 day before and 1 day after induction of ICH according to the dosing recommended by the manufacturer (0.2 mL/20–25 g). Four days after induction of ICH, the number of F4/80⁺ macrophages in the spleen was examined by flow cytometry to determine the efficiency of macrophage depletion.

**Fingolimod Administration**

According to previously reported methods, fingolimod (Gilenya; Novartis Pharmaceuticals Corporation, East Hanover, NJ) was dissolved in 2% dimethyl sulfoxide (DMSO). Mice were divided into 4 groups: sham-operated, ICH+vehicle (vehicle), ICH+fingolimod (1 mg/kg, i.p.) 5 minutes before ICH (fingolimod), and ICH+repeated fingolimod injection (1 mg/kg, i.p.; fingolimod+R, once 5 minutes before ICH and once daily for the next 3 consecutive days after ICH). Both the sham- and vehicle-treated groups received the same volume of 2% DMSO i.p.

**SsnB Administration**

Our previous research revealed that sparstolonin B (SsnB) reduces lipopolysaccharide-induced Nuclear factor kappa B (NF-κB) activity in a dose-dependent manner, and the half-maximal inhibitory concentration of SsnB is ≈10 μmol/L.²⁶ For in vitro experiments, SsnB (1, 10, or 50 μmol/L) was dissolved in polyethylene glycol 400 and added to the cell culture medium for 3 hours. For in vivo experiments, SsnB was injected intravenously into mice at a dose of 1, 5, or 10 mg/kg at 2 hours after induction of ICH with different administration protocols (twice a day, once daily, or once every 2 days for 3 successive days). Because a dose of 5 mg/kg once daily achieved the maximum inhibitory effect on neurologic deficit score (NDS) after ICH (data not shown), the protocol (5 mg/kg SsnB injected 2 hours after ICH and once daily for the next 3 consecutive days) was used to test the therapeutic effects of SsnB on ICH mice. Mice in the control group received the same volume of vehicle.

**Cell Culture**

**Bone marrow DCs**

As previously described, BM was collected from the tibias and femurs of C57BL/6, TLR2⁻/-, TLR4⁻/-, TLR2⁻/-/TLR4⁻/-, MyD88⁻/-, and TRIF⁻/- mice. BM cells were passed through a nylon mesh and then cultured for 8 days in RPMI-1640 medium with 10% fetal calf serum and 1 μg/mL mouse granulocyte-macrophage colony-stimulating factor Recombinant Protein (eBioscience, San Diego, CA).

**HEK-293 cells**

Human embryonic kidney (HEK)-293 cells for use in transfection experiments were obtained from ATCC (American Type Culture Collection, Manassas, VA) and cultured in high glucose–containing Dulbecco’s modified Eagle medium (Life Technologies, Carlsbad, CA) supplemented with 10% fetal bovine serum (Life Technologies).

**Real-Time PCR Analysis**

Real-time polymerase chain reaction (PCR) analysis was performed with the primers listed in Table S1, according to the manufacturer’s instructions (Takara Biotechnology, Dalian, China). The reaction conditions were as follows: 95°C for 30 seconds; 40 cycles of 95°C for 30 seconds, 60°C for 30 seconds, and 72°C for 1 minute; followed by 72°C for 5 minutes. The 2⁻ΔΔCT method was applied to calculate levels of mRNA expression relative to that of β-actin.

**Western Blot Analysis**

According to previously reported methods, proteins from perihematoma tissues were resolved by sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto polyvinylidene fluoride membranes via electroblotting. Membranes were incubated with IL-23p19 antibody (rabbit polyclonal antibody to IL-23p19, 1:200, Abcam, Cambridge, UK) or IL-17 antibody (rabbit polyclonal antibody to IL-17, 1:400; Abcam) at 4°C overnight, and the next day membranes were incubated with horseradish peroxidase–conjugated goat antimouse secondary antibody (1:300; Santa Cruz Biotechnology, Santa Cruz, CA) at 25°C for 1.5 hour. A chemiluminescence detection system was used to observe the resulting protein bands.

**Immunoprecipitation**

Cultured cells or infiltrating inflammatory cells sorted by fluorescence-activated cell sorting (FACS) were lysed in radio immunoprecipitation assay (RIPA) lysis buffer as previously described. The extracted protein was then incubated with antibody to mouse TLR2 (1:100, Abcam), TLR4 (1:100, Abcam), or IgG as a control (1:100, Abcam) at 4°C overnight, followed by addition of unblocked protein A beads (1:400, Abcam) for 2 hours. After centrifugation, the immunoprecipitates were
resuspended in SDS-PAGE buffer and subjected to Western blot analysis to quantify protein expression.

**Immunofluorescence and TUNEL Staining**

Immunofluorescence staining was performed on brain tissue sections (thickness of 25 μm) and cultured BM–derived DCs (BMDCs) using the primary and secondary antibodies listed in Table S2 as well as 4′,6-diamidino-2-phenylindole (DAPI; 0.5 μg/mL; Roche, Indianapolis, IN). For staining, samples were blocked with goat serum, incubated with the primary antibodies at 4°C overnight, washed, and then exposed to secondary antibodies at 25°C for 1 hour.

Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining was performed using the In Situ Cell Death Detection Kit of Roche Molecular Biochemicals (Mannheim, Germany), according to the manufacturer’s instructions.

All stained sections were examined using a confocal laser microscope (Leica, Hamburg, Germany). Positively stained cells were counted on the cortex around the hematoma. The number of positive cells within 3 regions of interest, each 0.1 mm² was expressed as an averaged value. Photomicrograph overlay and mild adjustment of contrast and brightness were achieved using Adobe Photoshop CS3 (Adobe Systems, San Jose, CA). Three trained researchers who were blinded to the grouping information performed the counting.

**Flow Cytometry**

**Preparation of inflammatory cells in perihematomaal tissues**

Single-cell suspensions of brain cells were prepared as previously described. Brieﬂy, at the designated time points, mice (n=5–8) were perfused transcardially using ice-cold PBS to clear blood cells before dissection of the forebrain from the cerebellum. The harvested brain tissue was suspended in RPMI-1640 medium and then digested in a 37°C shaker rotating at 180 rpm for 45 minutes upon addition of type IV collagenase (1 mg/mL; Sigma-Aldrich, St. Louis, MO) and DNase I (50 mg/mL, Roche). From the brain tissue, inflammatory cells were isolated by 37% to 70% Percoll (GE Healthcare) density gradient centrifugation as previously described and then washed with RPMI-1640 prior to flow cytometric analysis.

**Surface marker and intracellular cytokine staining**

For surface and intracellular cytokine staining, infiltrating inflammatory cells isolated by Percoll density gradient centrifugation as described above were stimulated for 5 hours with 50 nmol/L phorbol 12-myristate 13-acetate (Sigma-Aldrich), 1 μg/mL ionomycin (Sigma-Aldrich), and 1 μmol/L brefeldin A (eBioscience). Surface staining of infiltrating inflammatory cells from ICH brain tissue was performed with fluorescently labeled antibodies to the surface markers CD45-APC, CD3-perpcy5.5, CD4-PE/cy7, CD11b-FITC, γδT-PE, and Gr-1-PE (all from Biolegend, San Diego, CA) according to the manufacturer’s protocol (Biolegend) for 15 minutes. Different types of inflammatory cells were identified according to expression of specific markers as follows: macrophages (CD45⁹⁹⁹ CD11b⁹⁹⁹), microglia (CD45¹⁰⁰ CD11b⁷⁷⁷); neutrophils (CD45⁹⁹⁹ CD11b⁹⁹⁹ Gr-1¹); T lymphocytes (CD45⁹⁹⁹ CD3⁹⁹⁹); Th lymphocytes (CD45⁹⁹⁹ CD3⁹⁹⁹ CD4⁹⁹⁹); and γδT lymphocytes (CD45⁹⁹⁹ CD3⁹⁹⁹ CD4⁷⁷⁷ TCRγδ¹). After surface staining, the cells were resuspended in Fixation Buffer (eBioscience), and intracellular cytokine staining was performed using FITC-conjugated IL-17 (Biolegend) according to the manufacturer’s protocol.

**FACS analysis**

FACS analysis was performed using a FACSVerse analyzer (BD Biosciences, San Jose, CA), and the data were analyzed using FlowJo software 7.6.1 (FlowJo, LLC, Ashland, OR).

**NF-κB Activity**

According to a previously reported method, HEK-293 cells (ATCC, 1 × 10⁷) were transfected with both NF-κB-luciferase reporter gene (Addgen.org, plasmids 13642) and pcDNA3.1 vectors containing TLR2-YFP, TLR4-YFP, or MyD88 (Addgen.org, plasmids 13016, 13018, and 13026, respectively) and fused to yellow fluorescent protein (YFP). Mutation of the Arg196 of MyD88 was conducted as previously reported. Forty-eight hours after cotransfection, cells were stimulated under the specified conditions for 12 hours. Cells were subsequently lysed, and reporter gene activity was measured using a Dual Luciferase Assay Reporter System (E1910, Promega, Madison, WI).

**Liquid Chromatography-Mass Spectrometry**

Four days after ICH, WT mice were intravenously injected with SsnB at a dose of 5 mg/kg in polyethylene glycol 400, and mice in the control group received the same volume of vehicle intravenously. Cerebral tissues were sampled at 10, 20, and 30 minutes after injection. SsnB levels in the harvested samples were measured using liquid chromatography-mass spectrometry (LC-MS) (6410B Triple Quad LC/MS, Agilent Technologies, Palo Alto, CA).

**Brain Water Content**

Brain water content (BWC) was measured in mouse cerebral tissues after ICH as previously described. Brieﬂy, the
surface water on harvested cerebral tissue samples was blotted with filter paper, and the cerebellum and contralateral cerebral hemisphere were removed. Brain samples were immediately weighed on an electric analytic balance to obtain the wet weight and then dried at 100°C for 24 hours before measurement of the dry weight. BWC was calculated using the following formula: BWC (%)=(wet weight−dry weight)/wet weight×100%.

Neurologic Deficit Score

Multiple behavioral tests were applied to characterize neurologic deficits as previously reported. Two trained investigators who were blinded to animal grouping performed the scoring, and the final score for each mouse was obtained by calculating the mean scores for the subscales.

Statistical Analysis

All statistical tests were performed using SPSS 18.0 software (IBM, Armonk, NY), and all data are presented as the mean±standard error. The significance of differences between 2 and ≥3 groups was determined using nonparametric tests, Student t test, and 1-way ANOVA followed by Scheffe post hoc test, respectively. The effects of multiple factors were studied via 2-way ANOVA with repeated measures. For all tests, P<0.05 was considered statistically significant.

Results

Infiltration of Peripheral Inflammatory Cells and Their Involvement in Secondary Injury After ICH

After induction of ICH in WT C57BL/6 mice, the temporal changes in the numbers of different types of inflammatory cells in the hemorrhagic hemisphere were analyzed by FACS. Microglia and macrophages were gated according to the fluorescence intensity of CD45 and CD11b staining. The CD45high group was gated and further analyzed for the expression of CD3 and CD4. The CD45high CD3+ cells were gated and further analyzed for the expression of γδT (Figure S1). We observed the highest absolute numbers of CD45+ cells (Figure 1A), including T lymphocytes (CD3+ cells; Figure 1B), CD4+ T lymphocytes (Figure 1C), and γδT lymphocytes (Figure 1D), on day 4 after ICH, while the number of macrophages peaked at day 1 (Figure 1E). In contrast, no changes in the numbers of microglia were observed after ICH (Figure 1F). In confirmation of these FACS results, immunofluorescence staining showed that F4/80+ (macrophages/microglia; Figure 1G) and CD3+ cells (T lymphocyte; Figure 1H) were located along the perihematoma area after ICH.

Because the absolute numbers of macrophages peaked on day 1 after ICH, we first explored whether macrophage infiltration of the brain is required for ICH-induced injury by depleting peripheral macrophages using CLPs. In these liposomes, clodronate is encapsulated at a concentration of 7 mg/mL, and systemic administration with a dose of 0.2 mL/20 to 25 g has been demonstrated to achieve efficient depletion of macrophages within 24 to 36 hours. We confirmed depletion of 76.2% of F4/80+ macrophages in the spleen of ICH mice at 4 days after the first CLP injection (Figure S2). Intraperitoneal injection of CLPs also significantly reduced the number of infiltrating macrophages in the brain at 1 day and 4 days after ICH (Figure 2A), without influencing the infiltration of T lymphocytes (Figure 2B). Moreover, we found that CLP injection significantly reduced the NDS (Figure 2C) and BWC (Figure 2D) of WT mice with ICH. These findings that macrophage depletion alleviated ICH-induced brain damage in mice suggest that macrophage infiltration plays a key role in ICH-induced brain injury.

We next investigated the role of T lymphocytes in ICH-induced secondary brain injury by using fingolimod to inhibit T-lymphocyte migration. At day 4 after the ICH in mice treated with fingolimod, no change was observed in macrophage infiltration (Figure 2E), but T-lymphocyte infiltration was significantly reduced (Figure 2F). In addition, we also found that fingolimod treatment ameliorated the neurologic deficit (Figure 2G) and BWC (Figure 2H) changes induced by ICH in WT mice over 7 days. To confirm that these protective effects of fingolimod were related to reduced infiltration of peripheral T cells, we performed adoptive transfer of T lymphocytes into mice deficient in recombination activating gene-1 (Rag1−/− mice). First, we found that Rag1−/− mice exhibited a lower NDS (Figure 2I) and BWC (Figure 2J) than WT mice after ICH, which was consistent with previous results for experimentally induced ischemic stroke. Moreover, the NDS (Figure 2I) and BWC (Figure 2J) were increased when WT T lymphocytes were transferred into Rag1−/− mice. These results suggest that infiltrating peripheral T lymphocytes can aggravate secondary brain injury in mice after ICH.

Hb-Induced TLR2/TLR4 Heterodimer Formation on Infiltrating Macrophages Aggravated Secondary Brain Injury After ICH

Our previous research showed that hemoglobin (Hb) promotes microglial activation by inducing the formation of TLR2/TLR4 heterodimers and then exacerbates brain injury following ICH by amplifying the production of inflammatory cytokines. To determine whether Hb has a similar effect on infiltrating macrophages, we observed the colocalization of TLR2 and TLR4 on F4/80+ cells perihematomal in ICH mouse brain tissue by immunohistochemical staining (Figure 3A).
Figure 1. Macrophage and T-lymphocyte infiltration into mouse brain after intracerebral hemorrhage (ICH). A through F, Temporal changes in absolute numbers of different inflammatory cell types in hemorrhagic hemispheres at 1, 4, and 7 days after ICH. Data were obtained for cells pooled from 6 mice, and the experiments were repeated 3 times. *P<0.05, **P<0.01 vs sham. G, Representative fluorescence microscopy images showing infiltrating F4/80+ cells in the perihematoma area at 1 day after ICH (blue=4’-diamidino-2-phenylindole [DAPI], red=F4/80, scale bars=100 μm). H, Representative fluorescence microscopy images showing CD3+ cell infiltration into the perihematoma area at 4 days after ICH (blue=DAPI, green=CD3, scale bars=100 μm).
However, F4/80+ cells included not only macrophages but also microglia. To clarify whether TLR2 and TLR4 colocalized on macrophages, we stimulated BMDCs with Hb (5 μmol/L, 3 hours) and observed colocalization of TLR2 and TLR4 on these cells (Figure 3B). Furthermore, to investigate the link between TLR2 and TLR4 on macrophages, we cultured BMDCs from WT mice and separated macrophages from the brain or spleen of WT mice at day 1 after ICH. Then immunoprecipitation assays were performed to detect the coprecipitation of TLR2 and TLR4 in those cells. Among the red blood cell
components Hb, hemin, bilirubin, Fe\(^{2+}\), and Fe\(^{3+}\), only Hb was found to induce coprecipitation of TLR2 and TLR4 (Figure 3C). Immunoprecipitation assays also revealed that Hb induced coprecipitation of TLR2 and TLR4 on brain-derived macrophages of ICH mice, but not on spleen-derived macrophages (Figure 3D). These findings suggest that Hb induces TLR2/TLR4 heterodimer formation on macrophages located specifically in the brain but not in the peripheral region.

To test whether TLR2/TLR4 heterodimer on hematopoietic cells rather than resident brain cells plays a key role in ICH-induced secondary injury, we used BM-chimeric mice. The NDS (Figure 3E), BWC (Figure 3F), and number of apoptotic neurons (Figure 3G and 3H) were lower in WT mice that received TLR2\(^{-/-}\)/TLR4\(^{-/-}\) BM cells compared with those in TLR2\(^{-/-}\)/TLR4\(^{-/-}\) BM cells that received WT BM cells.

**IL-23p19 Produced by Infiltrating Macrophages Exacerbated Secondary Brain Injury Following ICH**

IL-23p19 is known to play key roles in the establishment and maintenance of organ-specific inflammatory autoimmune diseases.\(^{18,19,35,36}\) To study IL-23p19 involvement in ICH-induced brain injury, Western blot and real-time PCR analyses were performed to detect IL-23p19 expression at days 1, 4, and 7 after ICH. Compared with those in sham controls, IL-23p19...
IL-23/IL-17 Axis Aggravates Brain Injury After ICH

Zhong et al

DOI: 10.1161/JAHA.116.004340
Journal of the American Heart Association

23p19 role of IL-23p19, we compared ICH injury levels between IL-23p19−/− mice and WT mice. IL-23p19−/− mice showed a lower NDS (Figure 4C) and BWC (Figure 4D) and fewer apoptotic neurons after ICH (Figure 4E and 4F) than WT mice. In addition, IL-1β and tumor necrosis factor-α (TNF-α) gene expression in infiltrating CD45+ cells was significantly lower in IL-23p19−/− mice than in WT mice at day 4 after ICH (Figure 4G). These results suggest that IL-23p19 contributed to brain injury after ICH, which prompted us to next investigate the source of IL-23p19 in the injured brain.

IL-23p19 mRNA expression on infiltrating inflammatory (CD45+) cells was highest at day 1 after ICH (Figure 4H), corresponding to the peak in macrophage infiltration after ICH. Upon sorting of the infiltrating inflammatory cells into macrophages, microglia, and “other” cells (Figure S3), IL-23p19 mRNA was found to be expressed dominantly in the macrophages, with little expression in microglia and other protein (Figure 4A) and mRNA (Figure 4B) levels were significantly higher in the perihematoma tissues of ICH mice, peaking on day 1 after ICH (Figure 4A and 4B). To further elucidate the role of IL-23p19, we compared ICH injury levels between IL-23p19−/− mice and WT mice. IL-23p19−/− mice showed a lower NDS (Figure 4C) and BWC (Figure 4D) and fewer apoptotic neurons after ICH (Figure 4E and 4F) than WT mice. In addition, IL-1β and tumor necrosis factor-α (TNF-α) gene expression in infiltrating CD45+ cells was significantly lower in IL-23p19−/− mice than in WT mice at day 4 after ICH (Figure 4G). These results suggest that IL-23p19 contributed to brain injury after ICH, which prompted us to next investigate the source of IL-23p19 in the injured brain.

IL-23p19 mRNA expression on infiltrating inflammatory (CD45+) cells was highest at day 1 after ICH (Figure 4H), corresponding to the peak in macrophage infiltration after ICH. Upon sorting of the infiltrating inflammatory cells into macrophages, microglia, and “other” cells (Figure S3), IL-23p19 mRNA was found to be expressed dominantly in the macrophages, with little expression in microglia and other...
IL-23/IL-17 Axis Aggravates Brain Injury After ICH
Zhong et al

After ICH, IL-23p19 mRNA expression in perihematoma tissues was markedly decreased in the CLP mice compared with the vehicle-treated groups (Figure S2C). These data indicate that infiltrating macrophages were the major source of IL-23p19 in the mouse brain after ICH.

To verify whether Hb is essential for IL-23p19 production, we cultured BMDCs with different concentrations of Hb for 1, 3, and 6 hours. Stimulation with 5 μmol/L Hb for 3 hours led to the greatest IL-23p19 production (Figure 4J), and, thus, this concentration and stimulation duration were used in subsequent experiments. Next, we investigated the relationship between TLR2/TLR4 heterodimer formation and IL-23 production. Hb-mediated induction of IL-23p19 expression was lower in TLR2−/− and TLR4−/− BMDCs than in WT BMDCs and lower still in TLR2−/−/TLR4−/− BMDCs (Figure 4K).

Given that MyD88 and TRIF are independent adaptor proteins in the TLR signaling pathway, they also may be involved in the Hb-mediated expression of IL-23p19 in BMDCs. We found that MyD88−/− BMDCs produced less IL-23p19 than WT BMDCs (Figure 4K), whereas IL-23p19 production was comparable between TRIF−/− and WT BMDCs. These results suggest that IL-23p19 expression relies on TLR2/TLR4 heterodimer formation in a MyD88-dependent manner.

**γδT+ T Lymphocyte Produced IL-17 in Brain Injured by ICH**

IL-23 has been shown to induce CD4+ T-cell differentiation into Th17 cells, and this IL-23/IL-17 axis plays a central role in several inflammatory diseases. Thus, we examined the role of IL-17 in ICH-induced brain injury by intracellular cytokine staining and found enrichment of IL-17+ cells in the perihematoma tissue at day 4 after ICH (Figure 5A), which corresponds to the peak in T-lymphocyte infiltration. To examine the source of IL-17 in the injured brain, we performed immunostaining for various surface markers along with intracellular cytokine staining and found that IL-17 was colocalized with CD3 in the perihematoma area at 4 days after ICH (Figure 5B), but absent in CD11b+, βIII tubulin+, and GFAP+ cells (data were not shown), indicating that T lymphocytes were likely the source of IL-17 in ICH brain, which was further confirmed by FACS data (Figure S4).

Flow cytometric analysis of γδT and CD4 expression on IL-17+ CD3+ T cells indicated that most IL-17+–producing T lymphocytes were CD4− γδT+ cells (Figure 5C).

To confirm the relationship between IL-23 and IL-17 production in the ICH brain, we examined the percentage of IL-17+ cells among infiltrating CD3+ T lymphocytes in IL-23p19−/− mice. The lower percentage of IL-17+ CD3+ T lymphocytes in these mice (Figure 5D and 5E) suggests that IL-23p19 is essential for production of IL-17 after ICH.

Finally, to verify the contribution of γδT lymphocytes in ICH-induced brain injury, γδT+− mice were used. The NDS (Figure 5F), BWC (Figure 5G), and mRNA expression of IL-1β and TNF-α (Figure 5H) were significantly lower in γδT−/− mice than in WT mice after ICH.

**IL-17 Played a Critical Role in ICH-Induced Secondary Brain Injury**

To confirm the importance of IL-17 expression in ICH-induced secondary brain injury, we detected the dynamic expression of IL-17 in the mouse brain after ICH. Significant increases in both IL-17 protein (Figure 6A) and mRNA (Figure 6B) were observed from day 4 after ICH. We next compared the severity of ICH-induced injury between IL-17−/− mice and WT mice. IL-17−/− mice had significantly lower NDS (Figure 6C) and BWC (Figure 6D), and fewer apoptotic neurons were detected in IL-17−/− mice compared with WT mice (Figure 6E and 6F).

However, no differences in macrophage and T-lymphocyte infiltration in response to ICH were observed between IL-17−/− mice and WT mice (Figure 6G). Still, IL-1β and TNF-α mRNA expression in perihematoma tissues was significantly lower in IL-17−/− mice than in WT mice on day 4 after ICH (Figure 6H). CD45+ inflammatory cells in IL-17−/− mice also showed lower IL-1β and TNF-α mRNA expression on day 4 after ICH compared with these cells in WT mice (Figure 6I). Together, these findings indicate that elevated IL-17 expression aggranated secondary brain injury after ICH, and although IL-17 deficiency was not associated with decreased infiltration of inflammatory cells, increased expression of inflammatory factors including IL-1β and TNF-α may contribute to alleviation of ICH-induced injury.

**SsnB Ameliorated Secondary Brain Injury After ICH by Disrupting TLR2/TLR4 Heterodimer Formation**

Because our results indicate that TLR2/TLR4 heterodimer formation is essential for secondary injury following ICH, disruption of TLR2/TLR4 heterodimer formation may be a potential therapeutic strategy for ICH. We previously found that SsnB, a monomer component of Chinese traditional herbs (Figure S5A), can reduce lipopolysaccharide (LPS)-induced inflammatory injury, which suggested that SsnB may inhibit the TLR pathway. In the present study, immunoprecipitation indicated that SsnB inhibited TLR2/TLR4 heterodimer formation on cultured BMDCs (Figure 7A). We further examined the inhibitory activity of derivatives of SsnB (Figure S5B). SA3 treatment inhibited formation of TLR2/TLR4 heterodimer, whereas SsnB exhibited the greatest potential to inhibit TLR2/TLR4 heterodimer formation (Figure 7A). Furthermore, TLR2/TLR4 heterodimer formation
Figure 5. γδT-cell production of interleukin (IL)-17 after intracerebral hemorrhage (ICH). A, IL-17+ T lymphocytes identified by fluorescence-activated cell sorting (FACS) staining at 1, 4, and 7 days after ICH. Data were obtained for samples pooled from 5 mice, and the experiments were repeated 3 times, **P<0.05 vs sham. B, Immunofluorescence staining of CD3+ and IL-17+-positive cells in the perihematoma area of wild-type (WT) mice at 4 days after ICH (scale bars=20 μm). C, Flow cytometric analysis of γδT cell receptor (γδT) and CD4 expression on the CD3+IL-17+ T cells. Data were obtained for samples pooled from 5 mice, and the experiments were repeated 3 times. D and E, Percentages of IL-17+ cells among infiltrating T lymphocytes of WT, IL-17−/−, and IL-23−/− mice. Data were obtained for samples pooled from 5 mice, and the experiments were repeated 3 times. **P<0.01 vs WT. F, Neurologic deficit score (NDS) for WT and γδT−/− mice as analyzed at 1, 4, and 7 days after ICH. *P<0.05 vs WT, n=5. Two-way ANOVA reported significant difference in main effects of genotype (P<0.05) but not of time points (P>0.05), there was no interaction between genotype and time points (P>0.05). G, Brain water content for WT and γδT−/− mice as analyzed at 1, 4, and 7 days after ICH. *P<0.05 vs WT, n=5. H, IL-1β and tumor necrosis factor-α (TNF-α) mRNA levels in infiltrating CD45+ cells of WT and γδT−/− mice at day 4 after ICH. *P<0.05, **P<0.01 vs WT, n=4.
was inhibited by SsnB in a dose-dependent manner (Figure 7B), with a high dose (50 \( \mu \)mol/L) of SsnB completely abolished Hb-induced TLR2/TLR4 heterodimer formation (Figure 7B). Based on the involvement of TLR2/TLR4 heterodimer in Hb-mediated expression of IL-23p19, we detected IL-23p19 in SsnB-treated BMDCs and observed a reduction in IL-23p19 expression (Figure 7C).

NF-\( \kappa \)B activity assays were performed to test the ability of SsnB to inhibit the inflammatory reaction. Before the test, HEK-293 cells were transfected with TLR2, TLR4, and MyD88 containing pcDNA3.1. SsnB significantly inhibited NF-\( \kappa \)B activity in HEK-293 cells transfected with both TLR2 and TLR4, but the activity remained unchanged in HEK-293 cells expressing only TLR2 or TLR4 (Figure 7D). These results indicate that SsnB inhibited NF-\( \kappa \)B activity by interrupting TLR2/TLR4 heterodimer formation. Furthermore, compared with that in control MyD88-expressing HEK-293 cells, NF-\( \kappa \)B activity was significantly reduced in MyD88 nonexpressing HEK-293 cells (Figure 7E). This finding confirmed that MyD88 was essential for TLR2/TLR4 heterodimer formation, and the inhibitory effect of SsnB may be related to MyD88. Our previous research demonstrated that mutation of residue Arg196 of MyD88 can interrupt TLR2/TLR4 dimerization,\(^{22}\) which together with our present findings suggests that residue Arg196 on MyD88 may be the active site of SsnB.

In support of this notion, a mutation assay showed that NF-\( \kappa \)B activity was significantly inhibited when SsnB was added to HEK-293 cells expressing normal MyD88, while the NF-\( \kappa \)B activity was both significantly inhibited in cells expressing mutant MyD88 and showed no significant difference with the absence or presence of SsnB (Figure 7E).

To further investigate whether SsnB treatment benefits ICH model mice, we first examined the ability of SsnB to cross the BBB. Indeed, SsnB was detected in the brains of
ICH mice by LC-MS (Figure S6). Then, the effect of SsnB on ICH-induced injury in mice was evaluated. SsnB (5 mg/kg) was injected intravenously into mice 2 hours after ICH and then once daily for the next 3 days. Compared with the vehicle treatment, SsnB treatment led to a decreased NDS (Figure 7F), BWC (Figure 7G), and expression of proinflammatory factors including IL-23p19, IL-17 (Figure 7H), IL-1β, and TNF-α (Figure 7I). In addition, SsnB had no effect on the rectal temperature and peripheral white cell counts before and after ICH (Table S3), which suggests that SsnB treatment did not increase the risk of secondary infection. Together, our data indicate that SsnB significantly inhibited TLR2/TLR4 heterodimer formation and ameliorated secondary brain injury after ICH.
Discussion

The peripheral inflammatory cells responsible for neuroinflammation play important roles in the secondary brain injury that occurs after ICH, but the precise roles and mechanisms remain to be elucidated. The results of the present study revealed that infiltrating macrophages and γδT cells could worsen the secondary injury after ICH. We found that: (1) Hb from the hematoma could activate infiltrating macrophages to secrete IL-23 by inducing formation of toll-like receptors (TLRs) 2/4 heterodimer. Activated microglia release cytokines and chemokines to promote blood-brain barrier (BBB) breakdown. Thereafter, peripheral blood cells begin to infiltrate into the perihematoma brain during the acute phase of ICH (6–24 hours after ICH onset). In this phase, Hb activates the infiltrating macrophages via TLR2/TLR4 heterodimer. Activated macrophages produce interleukin (IL)–23. In the delayed phase of ICH (>24 hours after ICH onset), IL-23 induces IL-17 production from γδT cell receptor cells and causes further brain injury.

Our previous research revealed that during the hyperacute phase (<6 hours) of ICH, Hb from the hematoma can induce TLR2/TLR4 heterodimer formation on microglia. In the present study, we also found that only Hb from the hematoma could induce heterodimer formation on BMDCs, whereas other components including hemin, bilirubin, Fe²⁺, and Fe³⁺ have little effect on formation of the heterodimer. Furthermore, the TLR2/TLR4 heterodimer could only be detected on macrophages that had infiltrated the central nervous system, but not on the peripheral macrophages in the spleen. These results suggest that formation of the heterodimer may be closely related to the CNS microenvironment. Finally, compared with those of WT BM-transplanted TLR2⁻/⁻/TLR4⁻/⁻ mice, the NDS, BWC, and percentage of apoptotic neurons were all significantly decreased in TLR2⁻/⁻/TLR4⁻/⁻ BM-transplanted WT mice. Thus, the heterodimer on peripheral inflammatory cells plays a more important role than the heterodimer on the resident microglia. In conclusion, Hb from the hematoma could induce activation of both microglia and macrophages by inducing TLR2/TLR4 heterodimer formation, but the infiltrating macrophages may be more important in ICH-induced inflammatory injury. Accordingly, another study also indicated that macrophages have higher phagocytic and

Figure 8. Schematic model of the roles of inflammatory cells and cytokines in intracerebral hemorrhage (ICH)–induced secondary brain injury. In the hyperacute phase of ICH (within 6 hours after ICH onset), hemoglobin (Hb) is released from red blood cells and activates microglia by inducing the formation of toll-like receptors (TLRs) 2/4 heterodimer. Activated microglia release cytokines and chemokines to promote blood-brain barrier (BBB) breakdown. Thereafter, peripheral blood cells begin to infiltrate into the perihematoma brain during the acute phase of ICH (6–24 hours after ICH onset). In this phase, Hb activates the infiltrating macrophages via TLR2/TLR4 heterodimer. Activated macrophages produce interleukin (IL)–23. In the delayed phase of ICH (>24 hours after ICH onset), IL-23 induces IL-17 production from γδT cell receptor cells and causes further brain injury.
IL-23/IL-17 Axis Aggravates Brain Injury After ICH  Zhong et al

inflammatory potential than the microglia at the onset of neuroinflammation.38

Peroxiredoxin originating from degenerating neurons was shown to induce macrophage release of IL-23 through TLR2 and TLR4 signaling, which is an initiator of postischemic inflammation in the brain.21 Our present data first indicated that hematoma-derived Hb activated macrophage release of IL-23 by inducing the formation of TLR2/TLR4 heterodimer after ICH. This finding suggests that the Hb-induced TLR2/TLR4 heterodimer initiates neuroinflammation following ICH. Therefore, disruption of TLR2/TLR4 heterodimer formation may represent a new treatment strategy for ICH.

Our results indicating that macrophages are the main source of IL-23 and γδT cells are the main source of IL-17 in the hemorrhagic hemisphere are consistent with the findings of several previous studies involving inflammatory diseases. Shichita et al20 showed that IL-23 is expressed by infiltrating macrophages from the initiation of stroke and is an essential inducing factor for IL-17 production by γδT cells in the delayed phase of cerebral ischemia in mice as well as that IL-17–producing γδT cells have an important function during late-stage brain infarction and are the main source of IL-17, rather than Th17 cells. Another recent study demonstrated that γδT cells are an important source of IL-17 and can act in an amplification loop to promote IL-17 production by Th17 cells in EAE.17 Accordingly, in our study, IL-17– and γδT-deficient mice showed marked reductions in brain edema and neurologic deficits compared with WT mice. In addition, the number of macrophages and IL-23 expression in perihematomatous regions peaked at 1 day after ICH, whereas the number of γδT cells and IL-17 expression in these tissues peaked at 4 days after ICH. Together, these findings suggest that macrophages infiltrated the tissue immediately after ICH (acute phase, 6–24 hours post-ICH) and secreted elevated levels of IL-23, whereas γδT cells infiltrated the brain tissue in the delayed phase (>24 hours) of ICH and released IL-17 to exert a detrimental function. Furthermore, we observed that the number of IL-17+ cells was significantly lower in IL-23−/− mice after ICH, further indicating that IL-17 production is dependent on IL-23 expression. Although our results indicate that IL-17 production by γδT cells is essential in secondary brain injury of ICH, the precise role of IL-17 in inducing brain damage is not well understood and the target cells of IL-17 in the central nervous system remain unclear. Moreover, several cell types beyond only T-helper cells are capable of producing IL-17, including natural Th17 cells and innate lymphoid cells.39–41

Administration of SsnB 2 hours after ICH dramatically reduced neuroinflammation corresponding to the secondary injury. Because microglia are activated within minutes after ICH, inhibition of TLR2/TLR4 heterodimer formation on microglia seems difficult. Macrophages instead accumulate and become activated during the first 24 hours after ICH, which offers a prolonged therapeutic window. We propose that the clinical benefit of SsnB administered 2 hours after ICH may be due to inhibition of heterodimer formation on macrophages. Furthermore, we demonstrated that SsnB can penetrate the BBB, which is important for inhibition of neuroinflammation in ICH. Nonetheless, inflammation is generally considered a “double-edged sword,” because the use of anti-inflammatory drugs may increase the risk of secondary infection. Our findings that SsnB had no effect on rectal temperature and peripheral white cell counts before and after ICH suggest that SsnB did not increase the chance of secondary infection after ICH in our model. Therefore, SsnB warrants further testing as a potentially safe and efficient agent in ICH therapy.

Conclusions

The present study showed that Hb from the hematoma formed upon ICH induced the formation of TLR2/TLR4 heterodimer to activate IL-23 secretion by infiltrating macrophages. This macrophage-derived IL-23 induced γδT cell production of IL-17, which exacerbated the secondary brain injury after ICH in mice by amplifying the secretion of proinflammatory factors (Figure 8). Finally, SsnB may be able to ameliorate secondary brain injury in ICH by disrupting the formation of TLR2/TLR4 heterodimer.

Sources of Funding

This work was supported by grants from the National Natural Science Fund for Distinguished Young Scholars (81525008), National Science Foundation of China (81400974), and the National Basic Research Program of China (973 Program) (2014CB541605).

Disclosures

None.

References

1. Cheung RT. Update on medical and surgical management of intracerebral hemorrhage. Rev Recent Clin Trials. 2007;2:174–181.
2. Zhou M, Wang H, Zhu J, Chen W, Wang L, Liu S, Li Y, Liu Y, Yin P, Liu J, Yu S, Tan F, Barber RM, Coates MM, Dicker D, Fraser M, Gonzalez-Medina D, Hamavid H, Hao Y, Hu G, Jiang G, Kan H, Lopez AD, Phillips MR, She J, Vos T, Wan X, Xu G, Yan LL, Yu C, Zhao Y, Zou X, Naghavi M, Wang Y, Murray CJ, Yang G, Liang X. Cause-specific mortality for 240 causes in China during 1990–2013: a systematic subnational analysis for the Global Burden of Disease Study 2013. Lancet. 2016;387:251–272.
3. Qureshi AI, Mendelow AD, Hanley DF. Intracerebral haemorrhage. Lancet. 2009;373:1632–1644.
4. Xi G, Keep RF, Hoff JT. Mechanisms of brain injury after intracerebral haemorrhage. Lancet Neurol. 2006;5:53–63.
5. Mendelow AD, Gregson BA, Fernandes HM, Murray GD, Teasdale GM, Hope DT, Karimi A, Shaw MD, Barer DH. Early surgery versus initial conservative...
Treatment in patients with spontaneous supratentorial intracerebral haemato-
tomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH): a randomised trial. *Lancet*. 2005;365:387–397.

6. Mayer SA, Brun NC, Begtrop K, Broderick J, Davis S, Diringer MN, Skolnick BE, Steiner T. Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. *N Engl J Med*. 2008;358:2127–2137.

7. Aronowski J, Zhao X. Molecular pathophysiology of cerebral hemorrhage: secondary brain injury. *Stroke*. 2011;42:1781–1786.

8. Wang J. Preclinical and clinical research on inflammation after intracerebral hemorrhage. *Prog Neurobiol*. 2010;92:463–477.

9. Hwang BY, Appelboom G, Ayer A, Kellner CP, Kotchetkov IS, Gigante PR, Aronowski J, Zhao X. Molecular pathophysiology of cerebral hemorrhage: potential therapies for intracerebral hemorrhage. *Cerebrovasc Dis*. 2011;31:211–222.

10. Wang J, Dore S. Inflammation after intracerebral hemorrhage. *J Cereb Blood Flow Metab*. 2007;27:894–908.

11. Wang J, Dore S. Heme oxygenase-1 exacerbates early brain injury after intracerebral hemorrhage. *Brain*. 2007;130:1643–1652.

12. Rolland WB II, Manenoa K, Lekic T, Hasegawa Y, Ostrowski R, Tang J, Zhang JH, FTY720 is neuroprotective and improves functional outcomes after intracerebral hemorrhage in mice. *Acta Neurochir Suppl*. 2011;111:213–217.

13. Fu Y, Hao J, Zhang N, Ren L, Sun N, Li YJ, Yan Y, Huang D, Yu C, Shi FD. Fingolimod for the treatment of intracerebral hemorrhage: a 2-arm proof-of-concept study. *JAMA Neurol*. 2014;71:1092–1101.

14. Sansing LH, Harris TH, Kasner SE, Hunter CA, Kariko K. Neutrophil depletion attenuates intracerebral hemorrhage-induced brain injury. *Stroke*. 2014;45:2107–2114.

15. Lock C, Hermans G, Pedotti R, Brendolan A, Schadt E, Garren H, Langer-Gould A. Fingolimod for the treatment of intracerebral hemorrhage: a 2-arm proof-of-concept study. *JAMA Neurol*. 2014;71:1092–1101.

16. Sutton C, Brereton C, Keogh B, Mills KH, Lavelle EC. A crucial role for peroxiredoxin family proteins are promoters of acute ischemic stroke in mice by inducing dysfunction of the cerebral microvasculature. *Acta Neurochir Suppl*. 2011;113:571–591.

17. Liang Q, Wu Q, Jiang J, Duan J, Wang C, Smith MD, Lu H, Wang O, Nagarkatti P, Fan D. Characterization of sparstolon B, a Chinese herb-derived compound, as a selective Toll-like receptor antagonist with potent anti-inflammatory properties. *J Biol Chem*. 2011;286:26470–26479.

18. Weisfenfeldt J, Porse B. Bone marrow-derived macrophages (BMM): isolation and applications. *CSH Protoc*. 2008;2008: pdb prot5080.

19. Marasco E, Javed I, Na SY, Kahn A, Liesz A, Veltkamp R. Leukocyte invasion of the brain after experimental intracerebral hemorrhage in mice. *Stroke*. 2014;45:2107–2114.

20. Loftspring MC, McDole J, Lu A, Clark JF, Johnson AJ. Intracerebral hemorrhage leads to infiltration of several leukocyte populations with concomitant pathophysiological changes. *J Cereb Blood Flow Metab*. 2009;29:137–143.

21. Campanella M, Scoricati C, Tarozzo G, Beltramo M. Flow cytometric analysis of inflammatory cells in ischemic rat brain. *Stroke*. 2002;33:586–592.

22. Zhao X, Zhang Y, Strong R, Grotta JC, Aronowski J. 15d-Prostaglandin J2 activates peroxisome proliferator-activated receptor-gamma, promotes expression of catalase, and reduces inflammation, behavioral dysfunction, and neuronal loss after intracerebral hemorrhage in rats. *J Cereb Blood Flow Metab*. 2006;26:811–820.

23. Gliem M, Mausbach AK, Lee JJ, Simlantionakis I, van Roojen N, Hartung HP, Jander S. Macrophages prevent hemorrhagic infarct transformation in murine stroke models. *Ann Neurol*. 2012;71:743–752.

24. Seiler P, Aichele P, Odermatt B, Hengartner H, Zinkernagel RM, Schwendener RA. Crucial role of marginal zone macrophages and marginal zone metallophilis in the clearance of lymphocytic choriomeningitis virus infection. *Eur J Immunol*. 1997;27:2626–2633.

25. Yamaz G, Anumugam TV, Stokes KY, Granger DN. Role of T lymphocytes and interferon-gamma in ischemic stroke. *Circulation*. 2006;113:2105–2112.

26. Hue S, Ahern P, Buonocore S, Kullberg MC, Cua DJ, McKenzie BS, Powrie F, Maloy KJ. Interleukin-23 drives innate and T cell-mediated intestinal inflammation. *J Exp Med*. 2006;203:2473–2483.

27. Yen D, Cheung J, Scheeren H, Polouet F, McClanahan T, McKenzie B, Kleinschek MA, Owyang A, Mattson J, Blumeneschen W, Murphy E, Sathe M, Cua DJ, Kastelein RA, Rennick D. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. *J Clin Invest*. 2006;111:1310–1316.

28. Liang QL, Lei LL, Cui X, Zou NS, Duan JA. Bioactive cisi-stilbenoids from the tubers of Scirpus yagara. *Fitoterapia*. 2013;84:170–173.

29. Yamasaki R, Lu H, Butovskiy O, Ohno N, Rietsch AM, Cialic R, Wu PM, Doykan CE, Lin J, Cotileur AC, Kidd G, Zorlu MM, Sun N, Hu W, Liu L, Lee JC, Taylor SE, Uehlein L, Dixon D, Gu J, Floruta CM, Zhu M, Charo IF, Weiner HL, Ransohoff RM. Differential roles of microglia and monocytes in the inflamed central nervous system. *J Exp Med*. 2014;211:1533–1549.

30. Conl HT, Peterson AC, Brane L, Huppier AL, Hernandez-Santos N, Whibley N, Garg AV, Simpson-Abelson MR, Gibson GA, Mamo AJ, Osborne LC, Bishu S, Ghilardi N, Siebenlist U, Watkins SC, Artsa D, McGeachy MJ, Gaffen SL. Oral-resident natural Th17 cells and gammadelta T cells control opportunistic Candida albicans infections. *J Exp Med*. 2014;214:2075–2084.

31. Marks BR, Nowhyth HD, Choi JY, Poohole AC, Odegard JM, Flavell RA, Craft J. Thymic self-reactivity selects natural interleukin 17-producing T cells that can regulate peripheral inflammation. *Nat Immunol*. 2009;10:1125–1132.

32. Sutton CE, Mielke LA, Mills KH. IL-17-producing gammadelta T cells and innate lymphoid cells. *J Exp Med*. 2012;214:1217–1231.

33. Aronowski J, Hall CE. New horizons for primary intracerebral hemorrhage treatment: experience from preclinical studies. *Neur Res*. 2005;27:268–279.

34. Schilling M, Besselmann M, Leonhard C, Mueller M, Ringelstein EB, Kiefer R. Microglial activation precedes and predominates over macrophage infiltration in transient focal cerebral ischemia: a study in green fluorescent protein transgenic bone marrow chimicer mice. *Exp Neurol*. 2003;183:25–33.
Supplemental Material
| Gene     | Primer                      | Product size (bp) |
|----------|-----------------------------|-------------------|
| IL-6     | sens: agttgcctcttgggactga   | 159               |
|          | revs: tccacgatttcccagagaac |                   |
| IL-1β    | sens: gcccatctctgtgactcat   | 129               |
|          | revs: agctcatatggtccgacag  |                   |
| TNF-α    | sens: agaagttccccaaatggcctc| 120               |
|          | revs: ccacttgggtttgtacg    |                   |
| IL-17    | sens: tcctetgtgatctgggaag  | 154               |
|          | revs: ctgcacctgaaatggaagg  |                   |
| IL-23p19 | sens: tgctgattgcagagcagtaa | 121               |
|          | revs: gcctgagatccgagaga    |                   |
| β-actin  | sens: agattaactgtctggctctagc| 147               |
|          | revs: acctctctgactctggctttc|                   |

**Table S1.** Primers used for real-time PCR
**Table S2.** Primary and secondary antibodies used for immunofluorescence staining

| Antibodies                        | Catalog No. | Dilution | Source   |
|-----------------------------------|-------------|----------|----------|
| Mouse antimouse TLR2              | ab 119333   | 1:200    | Abcam    |
| Rabbit antimouse TLR4             | ab 13556    | 1:200    | Abcam    |
| Rat antimouse F4/80               | ab 6640     | 1:500    | Abcam    |
| Rabbit antimouse IL-23P19         | ab 45420    | 1:100    | Abcam    |
| Rabbit antimouse IL-17            | ab 79056    | 1:100    | Abcam    |
| Rat antimouse CD3                 | ab 33429    | 1:100    | Abcam    |
| Rat antimouse TLR2                | ab 11864    | 1:200    | Abcam    |
| Mouse antimouse βIII tubulin      | ab 78078    | 1:200    | Abcam    |
| Rabbit antirat IgG Alexa Fluor 488| A21210      | 1:500    | Invitrogen|
| Goat antirabbit IgG Alexa Fluor 568| A11011      | 1:500    | Invitrogen|
| Goat antimouse IgG Alexa Fluor 647| A21236      | 1:500    | Invitrogen|
| Parameter                      | Treatment group | Pre-ICH | 1 days post-ICH | 4 days post-ICH | 7 days post-ICH |
|-------------------------------|-----------------|---------|----------------|----------------|----------------|
| **Temperature (°C)**         | ICH+vehicle     | 36.9±0.2| 37.1±0.2       | 37.2±0.5       | 36.9±0.4       |
|                               | ICH+SsnB        | 37.0±0.4| 36.9±0.3       | 37.0±1.0       | 37.1±0.7       |
| **Peripheral white cell count** |                  |         |                |                |                |
| (×10⁹/L)                     | ICH+vehicle     | 7.46±2.25| 7.63±3.03      | 7.68±3.62      | 7.61±3.13      |
|                               | ICH+SsnB        | 7.39±2.31| 7.52±1.78      | 7.74±2.16      | 7.41±3.06      |

**Table S3.** Physiological parameters of mice before and after ICH
Figure S1.
Figure S2.

A

Vehicle

CLP

5.22%

1.24%

Count

F4/80

B

% of F4/80^+ cells in spleen

Vehicle

CLP

C

IL-23p19 (Folds vs sham)

sham

1d

4d

7d

Vehicle

CLP

**
Figure S3.

Figure S4.
Figure S5.

A

B

|     | SsnB | SA1 | SA2   | SA3   |
|-----|------|-----|-------|-------|
| R1  | OH   | H   | OCOCH₃| OH    |
| R2  | O    | O   | O     | NH    |
| R3  | OH   | OH  | OCOCH₃| OH    |

Figure S6.
Supplemental Figure Legends:

**Figure S1.** Macrophages, microglia, and other cell types were identified by FACS from pooled infiltrating inflammatory cells collected from 8 mice on day 4 after induction of ICH, according to the following markers: CD45\textsuperscript{high}CD11b\textsuperscript{high} cell were macrophages; CD45\textsuperscript{int}CD11b\textsuperscript{int} were microglia; CD45\textsuperscript{high}CD3\textsuperscript{+}CD4\textsuperscript{+} cells were defined as brain-invading T helper cells; and CD45\textsuperscript{high}CD3\textsuperscript{+} cells were further analyzed to identify γδT lymphocytes. FSC-A, forward scatter channel area; SSC-A, side scatter channel area.

**Figure S2.** Depletion of macrophages in the spleen upon clodronate liposome (CLP) treatment. (A) Percentages of F4/80\textsuperscript{+} macrophages in spleens of vehicle-treated and CLP-treated mice at 1 day after ICH determined by flow cytometric analysis. (B) Quantified percentages of F4/80\textsuperscript{+} macrophages in spleens of vehicle-treated and CLP-treated groups. (**p<0.01 vs. vehicle, n=5). (C) mRNA expression of IL-23p19 in perihematoma tissues at 1, 4, and 7 days after ICH in the CLP- and vehicle-treated mice. (**p<0.01 vs. vehicle, n=4).

**Figure S3.** Sorting of macrophages, microglia, and other cells from pooled infiltrating inflammatory cells collected from 7 mice at day 4 by FACS for subsequent evaluation of IL-23p19 expression. CD45\textsuperscript{high}CD11b\textsuperscript{high} cell were macrophages; CD45\textsuperscript{int}CD11b\textsuperscript{int} were microglia; and CD45\textsuperscript{+}, CD11b\textsuperscript{−} were grouped as “other” cells.
**Figure S4.** CD3+ T lymphocytes were the main source of IL-17. The indicated surface markers were used to identify IL-17–producing cells among pooled infiltrating inflammatory cells collected from 8 mice on day 4 after induction of ICH and sorted by FACS.

**Figure S5.** (A) Structures of SsnB and the compounds derived from SsnB. (B) Structure of J1, the isomorphic isomer of SsnB.

**Figure S6.** SsnB crosses the mouse blood-brain barrier. (A) Standard curve for SsnB. (B) SsnB concentrations in cerebral tissues of mice subjected to ICH and in the vehicle-treated group. (C) SsnB concentrations in cerebral tissues of ICH model mice at 10, 20, and 30 minutes after intravenous injection of SsnB.